Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

Braxia Scientific has announced positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of multi-dose psilocybin-assisted therapy for treatment-resistant depression.

Preliminary results indicate strong feasibility with adequate recruitment including 159 individuals who were referred to the study and clinically meaningful improvements in depression severity were observed.

Category Press Release
Published in PR Newswire

Companies Featured

Braxia Scientific
Braxia Scientific Corp (previously Champignon Brands and Apotheosis Scientific) is one of the for-profit companies developing therapies in conjunction with psychedelics. In its short history, it has acquired a psilocybin research firm Tassili Life Sciences, a mushroom cultivator (Artisan Growers), and has recently started offering esketamine treatments for MDD.